title: Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions.
abstract: BACKGROUND
  Patients with chronic renal insufficiency (CRI) have worse outcomes during and after percutaneous coronary interventions (PCI). Abciximab reduces complications, but may cause excessive bleeding in patients with CRI. Therefore, we sought to determine the safety of abciximab in patients with CRI.
  
  
  METHODS
  Patients (n = 4158) undergoing PCI at the Mayo Clinic since abciximab became available were analyzed according to their estimated creatinine clearance (> or =70, 50-69, or <50 mL/min) or need for dialysis. Major bleeding was defined as a cerebrovascular bleed or a decrease in the hematocrit level >15%. Minor bleeding was defined as a decrease in the hematocrit level of 10% to 15% with an identifiable site of bleeding.
  
  
  RESULTS
  CRI was associated with increased bleeding in patients who received abciximab and patients who did not. However, there was only a trend toward an interaction between creatinine clearance and major bleeding with abciximab (odds ratio [OR], 1.18; P =.06) and no interaction with minor bleeding (OR, 1.01; P =.94) or any bleeding (OR, 1.10; P =.15).
  
  
  CONCLUSIONS
  CRI is associated with an increased risk of bleeding complications after PCI. Although abciximab increases the risk of bleeding in all patients, the increase in relative risk is not significantly greater in patients with CRI. Thus, abciximab may be given safely in patients with CRI who are undergoing PCI.
authors.affiliation: Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA.
authors.forename: Patricia J M
authors.initials: PJ
authors.lastname: Best
authors.forename: Ryan
authors.initials: R
authors.lastname: Lennon
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Gersh
authors.forename: Henry H
authors.initials: HH
authors.lastname: Ting
authors.forename: Charanjit S
authors.initials: CS
authors.lastname: Rihal
authors.forename: Malcolm R
authors.initials: MR
authors.lastname: Bell
authors.forename: Charles A
authors.initials: CA
authors.lastname: Herzog
authors.forename: David R
authors.initials: DR
authors.lastname: Holmes
authors.forename: Peter B
authors.initials: PB
authors.lastname: Berger
mesh_terms: D000077284:Abciximab; D000368:Aged; D000704:Analysis of Variance; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D017023:Coronary Angiography; D003327:Coronary Disease / Q000150:complications / Q000628:therapy*; D003404:Creatinine / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012306:Risk
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D003404:Creatinine; D000077284:Abciximab